ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/QLD/4066-Auchenflower-Icon-Cancer-Centre-at-Wesley-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
26
trial(s) found.
NCT07851025
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan in Combination With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Treatment in Participants With Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (
TREVI-OC-02
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2500 - Wollongong - Wollongong Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3121 - Richmond - Epworth Freemasons Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT07816666
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of Torvutatug Samrotecan With or Without Bevacizumab Versus Standard of Care as Second- or Third-Line Maintenance Treatment in Participants With Platinum-sensitive Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (
TREVI-OC-03
)
anti-FR-alpha antibody-drug conjugate
anti-VEGF monoclonal antibody
Epithelial Ovarian Cancer
Fallopian tube cancer
Primary peritoneal serous carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07802704
Advanced
Phase 3
Recruiting
A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan, a B7-H3 Antibody Drug Conjugate (ADC) in Participants With Metastatic Castration-resistant Prostate Cancer (EMBOLD Prostate-302)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Cancer
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07720284
Curative
Phase 3
Recruiting
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (
TU-04
)
anti-Trop2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
Urothelial carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3168 - Clayton - Monash Medical Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3021 - St Albans - Western Health - Sunshine Hospital (WITHDRAWN)
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (WITHDRAWN)
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
NCT07686068
Advanced
Phase 1 / Phase 2
Not yet recruiting
Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors (
VBC106-01-01
)
bispecific-FR-alpha/MSLN antibody-drug conjugate
Cancer
Solid tumour
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07441694
Haem
Phase 1
Recruiting
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms (
INCA036978-101
)
unknown drug class
Myeloproliferative Neoplasm
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT07421700
Advanced
Phase 1 / Phase 2
Recruiting
AN INTERVENTIONAL PHASE 1B/2, OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, ANTITUMOR ACTIVITY, AND PHARMACOKINETICS OF PF 08634404 MONOTHERAPY OR IN COMBINATION WITH ENFORTUMAB VEDOTIN IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (
C6461006
)
anti-NECTIN4 antibody-drug conjugate
Urothelial carcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07286331
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy
anti-B7H4 antibody-drug conjugate
Endometrial carcinoma
NSW
2830 - Dubbo - Dubbo Base Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07286266
Advanced
Phase 3
Recruiting
A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer
anti-B7H4 antibody-drug conjugate
Ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07227415
Advanced
Phase 1 / Phase 2
Recruiting
AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA (
C6461008
)
bispecific PD-1/VEGF antibody
Clear cell renal cell carcinoma
Kidney cancer
VIC
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT07226349
Advanced
Phase 1
Recruiting
A Phase 1a/1b, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75098 Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors (
BG-75098-101
)
CDK2 inhibitor
Solid tumour
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - One Clinical Research
NCT07218809
Advanced
Phase 3
Recruiting
A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (
TREVI-OC-01
)
anti-FR-alpha antibody-drug conjugate
Epithelial Ovarian Cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2487 - Cudgen - Tweed Valley Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT07213674
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
CYP17A1 inhibitor
bispecific T-cell engager,STEAP1-targeting
Castrate-resistant prostate cancer
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Tasman Oncology (TERMINATED)
NCT07059845
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer (
FLORENZA
)
anti-FR-alpha antibody-drug conjugate
Ovarian cancer
Primary fallopian tube serous carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2217 - Kogarah - St George Private Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3121 - Richmond - Epworth Freemasons Hospital
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5065 - Toorak Gardens - Burnside War Memorial Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06890598
Curative
Phase 3
Recruiting
A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -
SUNRAY-02
KRAS G12C inhibitor,OFF-state inhibitor
placebo
Non-small cell lung cancer
NSW
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3630 - Shepparton - Goulburn Valley Health
3844 - Traralgon - Latrobe Regional Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06819007
Advanced
Phase 3
Recruiting
A Phase 3, Open-label, Multicenter, Randomized Trial of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144- O/GOG-3112/APGOT-OV13) (
DO-01
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-VEGF monoclonal antibody
Ovarian cancer
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - South Australia - GenesisCare St Andrews Hospital
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06649708
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies (
HX044-I-01
)
unknown drug class
Cancer
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
NCT06500273
Haem
Phase 2
Recruiting
A Randomized, Open-label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants With Minimal Residual Disease After Response to First Line Therapy for Large B-cell Lymphoma (
ALPHA3
)
allogeneic CAR-T-cell therapy,CD19-targeting
Diffuse large B-cell lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
WA
6009 - Nedlands - Hollywood Private Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06492616
Curative
Phase 3
Recruiting
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study (
ELEGANT
)
selective estrogen receptor degrader
Breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2060 - North Sydney - Mater Hospital
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2217 - Kogarah - St George Hospital
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2480 - Lismore - Lismore Base Hospital
VIC
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3135 - Ringwood East - Maroondah Hospital
3168 - Clayton - Monash Medical Centre
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - ICON Cancer Care
4812 - Hyde Park - Icon Cancer Centre Townsville
SA
5000 - Adelaide - Cancer Research SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - ICON Cancer Care Hobart
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Bladder cancer
Breast cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Sarcoma
Small-cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06119581
Advanced
Phase 3
Recruiting
SUNRAY-01
, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
placebo
Non-small cell lung cancer
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4215 - Southport - Gold Coast University Hospital
4575 - Birtinya - Sunshine Coast University Hospital
4740 - Mackay - Mackay Base Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06091865
Haem
Phase 3
Recruiting
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (
OLYMPIA-3
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
NCT06072781
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301) (
RAMP-301
)
FAK inhibitor
RAF/MEK clamp
Low-grade serous ovarian cancer
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05730036
Haem
Phase 3
Recruiting
An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (
LINKER-MM3
)
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - One Clinical Research
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
NCT05646862
Advanced
Phase 3
Recruiting
A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy (
INAVO121
)
PI3K alpha inhibitor
selective estrogen receptor degrader
Breast cancer
NOT HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (COMPLETED)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (WITHDRAWN)
VIC
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (COMPLETED)
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NA
NA (WITHDRAWN)
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
ACTRN12626001252303
Radonc
Not Applicable
Not yet recruiting
A multi-centre pilot study of 3-fractIoN CEliac Plexus RadioablaTION (
INCEPTION
): Evaluating the efficacy in reducing pain in adults with pancreatic cancer and cancer-related abdominal pain caused by involvement of the celiac plexus
Radiotherapy
cancer therapy
Cancer
Pancreatic cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3011 - Footscray - Footscray Hospital
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6014 - Wembley - GenesisCare Wembley
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (24)
Not yet recruiting (2)
Recruitment Country and State
QLD (25)
NSW (22)
VIC (21)
SA (12)
WA (12)
TAS (6)
NZ (2)
ACT (1)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (4)
Phase 2 (2)
Phase 3 (16)
Trial Type
Advanced (18)
Haem (4)
Curative (3)
Radonc (1)
Cancer Therapy Class
VEGF
27%
PD-1
23%
PD-1/PD-L1
23%
FR-alpha
15%
oestrogen axis
15%
ER
12%
B7H3
8%
CYP17A1
8%
androgen axis
8%
Nectin4
8%
PD-L1
8%
B7H4
8%
KRAS
8%
AR
4%
TIGIT
4%
Trop2
4%
CTLA4
4%
HIF2a
4%
KIT
4%
PDGFR
4%
VEGFR
4%
CDK2
4%
CDK4
4%
CDK4 selective
4%
STEAP1
4%
ERBB2
4%
CD19
4%
CD20
4%
BRAF
4%
CRAF
4%
FAK
4%
MEK
4%
RAF
4%
BCMA
4%
CS1
4%
cereblon
4%
PI3Kalpha
4%
Facility
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (26)
3168 - Clayton - Monash Medical Centre (9)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (8)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (4)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (4)
2031 - Randwick - Prince of Wales Hospital (3)
3121 - Richmond - Epworth Freemasons Hospital (3)
7000 - Hobart - Royal Hobart Hospital (3)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (3)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
2050 - Camperdown - Chris O'Brien Lifehouse (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
7000 - Hobart - ICON Cancer Care Hobart (3)
3630 - Shepparton - Goulburn Valley Health (3)
3065 - Fitzroy - St Vincent's Hospital Melbourne (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (2)
4217 - Benowa - Pindara Private Hospital (2)
5065 - Toorak Gardens - Burnside War Memorial Hospital (2)
2170 - Liverpool - Liverpool Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
2139 - Concord - Concord Repatriation General Hospital (2)
3002 - East Melbourne - Epworth Freemasons (2)
2109 - North Ryde - Macquarie University Hospital (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (2)
6009 - Nedlands - One Clinical Research (2)
2217 - Kogarah - St George Hospital (2)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (2)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
2500 - Wollongong - Wollongong Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
2830 - Dubbo - Dubbo Base Hospital (1)
2487 - Cudgen - Tweed Valley Hospital (1)
2605 - Garran - The Canberra Hospital (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4215 - Southport - Tasman Oncology (1)
2217 - Kogarah - St George Private Hospital (1)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (1)
2340 - Tamworth - Tamworth Hospital-North West Cancer Centre (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
5000 - South Australia - GenesisCare St Andrews Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2060 - North Sydney - Mater Hospital (1)
2290 - Gateshead - Genesis Cancer Care, Lake Macquarie Private Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
3066 - Epping - Northern Hospital (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
3135 - Ringwood East - Maroondah Hospital (1)
4215 - Southport - ICON Cancer Care (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
5000 - Adelaide - Cancer Research SA (1)
5011 - Woodville South - The Queen Elizabeth Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
4215 - Southport - Gold Coast University Hospital (1)
4740 - Mackay - Mackay Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
NA
3011 - Footscray - Footscray Hospital (1)
6014 - Wembley - GenesisCare Wembley (1)
Cancer Type
Cancer
Solid tumour
Gynaecological cancer
Ovarian cancer
Epithelial Ovarian Cancer
Urogenital cancer
Haematological malignancy
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Lung cancer
Non-small cell lung cancer
Respiratory tract cancer
Thoracic cancer
Breast cancer
Fallopian tube cancer
Urothelial carcinoma
Endometrial cancer
Clear cell renal cell carcinoma
Kidney cancer
Castrate-resistant prostate cancer
Male genital cancers
Prostate adenocarcinoma
Prostate cancer
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Gastrointestinal cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Pancreatic cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
Myeloproliferative neoplasm
Endometrial carcinoma
Primary fallopian tube serous carcinoma
Bladder cancer
Carcinoma
Cervical cancer
Colorectal cancer
Exocrine pancreatic cancer
Gastric cancer
Gastroesophageal cancer
HPV-related cancer
HPV16-positive cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Hepatobiliary cancer
Hepatocellular carcinoma
High-grade serous ovarian cancer
Lower gastrointestinal cancer
Melanoma
Neuroendocrine carcinoma
Oesophageal cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Viral-related cancer
Low-grade serous ovarian cancer
Multiple myeloma
Plasma cell disorder
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy